Second emergency use authorization granted for a Quest H1N1 flu test
This article was originally published in The Gray Sheet
Executive Summary
A second emergency use authorization request is granted to Quest's Focus Diagnostics unit by FDA Oct. 16 for an H1N1 influenza test. This one will allow Quest to market and offer its Simplexa Influenza A H1N1 (2009) test for use on the 3M Integrated Cycler. FDA granted an EUA July 24 to Quest for its Focus Diagnostics Influenza H1N1 (2009) real-time reverse transcription polymerase chain reaction test (1"The Gray Sheet" July 27, 2009). While 3M's Integrated Cycler diagnostic testing system is not FDA cleared or approved, when the Simplexa test is used on the 3M platform, it can provide increased capacity for 2009 H1N1 flu testing to a wide range of CLIA high-complexity laboratories, including hospital labs coping with a surge in testing demand this fall
You may also be interested in...
Gen-Probe H1N1 flu test
FDA grants emergency use authorization for Gen-Probe's Prodesse ProFlu-ST flu test, to be used in high-complexity CLIA labs to diagnose H1N1 influenza, firm announces Oct. 29. The reverse transcription polymerase chain reaction (RT-PCR) test employs an algorithm linked to seasonal influenza A/H1 and A/H3 virus test results. Other H1N1 flu tests granted EUAs in recent months include Quest Diagnostic's Simplexa Influenza A H1N1 (2009) and Focus Diagnostics Influenza H1N1 (2009) tests ("1The Gray Sheet" Oct. 26, 2009)
Regulatory News In Brief
Pandemic flu test: FDA granted emergency use authorization July 24 to a third diagnostic test for detecting the HINI pandemic flu virus, Quest Diagnostics Focus Diagnostics Influenza H1N1 (2009) real-time reverse transcription polymerase chain reaction test. The authorization, enabled by the 2004 Project BioShield law, permits Quest to distribute the test to clinical labs from its California-based Focus Diagnostics subsidiary. The assay can amplify viral genetic material obtained from nose or throat swabs, or nasal discharges, in patients with symptoms of respiratory infection. The previous two EUA tests were developed by the federal government
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.